⚠️ Research Use Only. This post is educational and does not constitute medical advice. All peptides discussed are sold for research purposes only. See our full disclaimer.
Overview
Thymosin Alpha-1 is a 28-amino-acid peptide produced by the thymus, studied extensively for immune modulation and used clinically in over 35 countries.
What is Thymosin Alpha-1?
Thymosin Alpha-1, often abbreviated Tα1, is a 28-amino-acid peptide naturally produced by the thymus gland. Among research peptides, it has one of the strongest clinical pedigrees — it's marketed pharmaceutically as Zadaxin and approved for use in over 35 countries for indications including chronic hepatitis B and C, as a vaccine adjuvant, and as adjunctive therapy in certain cancers.
Mechanistically, Tα1 acts as an immune system modulator rather than a stimulator or suppressor. It promotes T-cell maturation, enhances dendritic cell function, and helps balance Th1/Th2 immune responses — making it especially studied in conditions where immune signaling is disordered rather than simply too high or too low. Research during COVID-19 examined Tα1 in critically ill patients, with several studies reporting reduced mortality in hospitalized cohorts.
Dosing in clinical trials typically uses 1.6 mg subcutaneous, twice weekly. Research-grade Tα1 follows similar dosing in published literature. Side effects are minimal — Zadaxin's clinical record across decades shows one of the cleaner safety profiles in injectable biologics.
Thymosin Alpha-1 is often distinguished from Thymosin Beta-4 (TB-500's parent compound) — they are different molecules with different mechanisms despite the shared 'thymosin' name.
Top Research Uses
- Immune modulation
- Chronic infection research
- Cancer adjunct research
- Vaccine response
- Autoimmune research
Mechanism of Action
Activates T-cell maturation, modulates dendritic cells, and balances Th1/Th2 immune responses
Research Parameters
| Half-Life | ~2 hours |
| Typical Research Dose | Clinical research commonly cites 1.6 mg subq, twice weekly |
| Administration Route | Subcutaneous |
| Reported Side Effects | Very low side effect profile; rare injection site reactions or transient flu-like symptoms |
Dosing ranges cited from published research literature. These are not recommendations for human use. Thymosin Alpha-1 is a research compound — not for human consumption.
Research Strength: High
Thymosin Alpha-1 has a substantial body of preclinical research supporting its studied applications. Multiple independent studies have examined its mechanisms and effects in animal models.
Vendor & Sourcing Notes
Sold as the pharmaceutical product Zadaxin in many countries; research powder available domestically
Always request third-party HPLC purity reports and mass spectrometry verification when sourcing research peptides. Quality varies significantly between suppliers.
Research Use Only — Compliance Notice
The information on this page is intended for educational and informational purposes only. Thymosin Alpha-1 (Thymosin Alpha-1 (Tα1)) is a research compound sold for laboratory research purposes only. It has not been approved by the FDA for human use. Nothing on this page constitutes medical advice or is intended to diagnose, treat, cure, or prevent any disease. Statements have not been evaluated by the FDA. Consult a qualified healthcare professional before considering any peptide-related protocols.
